Advanced Oncotherapy #AVO – Final Results statement plus CEO and Chairmans report

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2017, another year of significant technological development and installation of the Company’s first LIGHT system. Key highlights: ·     Successful integration of three of the four key LIGHT system structures significantly reducing technical […]

Radiation for Mesothelioma: Could Proton Therapy Be the Answer? – Advanced Oncotherapy #AVO

Researchers at the Maryland Proton Therapy Treatment Center say that a highly-targeted version of proton beam radiation could be the future of radiotherapy for malignant plural mesothelioma. Advanced Oncotherapy #AVO, is developing a unique, fully integrated, proton therapy system. The LIGHT System is expected to be the first commercially available linear proton accelerator for medical treatment […]

Advanced Oncotherapy #AVO – Successful testing supports the superior clinical outcomes of LIGHT

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, provides the following technological update. The LIGHT system has been designed to electronically control the fast delivery of protons to the tumour site. This unique ability provides the opportunity to alter the exact amount of radiation that is given to every part of […]

Nicolas Serandour, CEO of Advanced Oncotherapy #AVO discusses Yantai deal & £37m equity investment with BRR Media

Nicolas Serandour, CEO of Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that they have signed an exclusive distribution agreement with Yantai CIPU Medical Technology to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. At the same time, the Company has secured £20.9 […]

Advanced Oncotherapy (AVO) – Technological milestones update – CCL units

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the completion of a further technological milestone in the manufacture of its first LIGHT system. Delivery of CCLs The Company confirms that the final Coupled Cavity Linac (CCL) module, to be used to generate a beam capable of treating superficial […]

Advanced Oncotherapy (AVO) – Hardman Research: Delivery of LIGHT

Delivery of LIGHT: AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction work on its Harley Street site expected to commence this month following preliminary assessment work. Meanwhile, individual modules for the LIGHT […]

Advanced Oncotherapy (AVO) – Financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces it has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm. The Agreement gives the Company the ability to issue a minimum of £13 million in convertible loan notes (Minimum […]

Advanced Oncotherapy (AVO) – Sinophi update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has come to an agreement with Sinophi Healthcare Limited to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. In addition, both parties have reached an agreement to terminate the distribution agreement also announced […]